AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36040184 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative oral electrolyte-carbohydrate nutrition supplement (OECNS)
Number of subjects: 94
Study 36040184 — intervention group
Group type: COMPARATOR
Intervention: Control group (meal nutrition supplements and water)
Number of subjects: 94
Study 33885704 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) starting dose of 50 Gy in 5 fractions (central lung, mediastinal/cervical lymph node), 45 Gy in 3 fractions (peripheral lung, abdominal-pelvic, liver), and 30 Gy in 3 fractions (bone/osseous, spinal/paraspinal)
Number of subjects: 35
Study 32072763 — intervention group
Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 2.5 mg once daily
Number of subjects: 126
Study 32072763 — intervention group
Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 10 mg once daily
Number of subjects: 126
Study 32072763 — intervention group
Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 25 mg once daily
Number of subjects: 126
Study 32072763 — intervention group
Group type: EXPERIMENTAL
Intervention: LIK066 (licogliflozin) 50 mg once daily
Number of subjects: 126
Study 32072763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 35044431 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic mesh
Number of subjects: 253
Study 35044431 — intervention group
Group type: COMPARATOR
Intervention: Biologic mesh
Number of subjects: 253
Study 35044431 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meshes
Number of subjects: 253
Study 33085532 — intervention group
Group type: EXPERIMENTAL
Intervention: Own mother's milk odor
Number of subjects: 90
Study 33085532 — intervention group
Group type: EXPERIMENTAL
Intervention: Another mother's milk odor
Number of subjects: 90
Study 33085532 — intervention group
Group type: COMPARATOR
Intervention: Control group (no milk odor)
Number of subjects: 90
Study 33237242 — intervention group
Group type: EXPERIMENTAL
Intervention: 17% EDTA
Number of subjects: 78
Study 33237242 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% EDTA
Number of subjects: 78
Study 33237242 — intervention group
Group type: COMPARATOR
Intervention: Control (distilled water)
Number of subjects: 78
Study 33237242 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX U200 (RX)
Number of subjects: 78
Study 33237242 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilink Speed (ML)
Number of subjects: 78
Study 35695053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulin (IVIG) at a dose of 5 g/day for 3 days (total 15 g or 0.3 g/kg)
Number of subjects: 80
Study 35695053 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intravenous immunoglobulin (IVIG)
Number of subjects: 80
Study 34474583 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban or rivaroxaban plus an antiplatelet agent
Number of subjects: 2215
Study 34474583 — intervention group
Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 2215
Study 35866981 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% sodium citrate with methylene blue and parabens
Number of subjects: 400
Study 35866981 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 400
Study 34961782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg
Number of subjects: 100
Study 34961782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Etodolac (ETO)
Number of subjects: 100
Study 34961782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Ketorolac (KET)
Number of subjects: 100
Study 34961782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Ibuprofen (IBU)
Number of subjects: 100
Study 34961782 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 8 mg + Loxoprofen (LOX)
Number of subjects: 100
Study 34961782 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol 750 mg (rescue analgesics)
Number of subjects: 100
Study 35590400 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain Frame Messages (GFM)
Number of subjects: 270
Study 35590400 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss Frame Messages (LFM)
Number of subjects: 270
Study 35590400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pamphlet)
Number of subjects: 270
Study 33203880 — intervention group
Group type: EXPERIMENTAL
Intervention: 3YF-lipin-1
Number of subjects: 0
Study 33203880 — intervention group
Group type: COMPARATOR
Intervention: p-Tyr-lipin-1 levels
Number of subjects: 0
Study 34287970 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg apraglutide
Number of subjects: 8
Study 34287970 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg apraglutide
Number of subjects: 8
Study 34287970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 34955789 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS with mindfulness practice
Number of subjects: 30
Study 34955789 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with mindfulness practice
Number of subjects: 30
Study 34933309 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water with Sinapis nigra (MU)
Number of subjects: 17
Study 34933309 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water with Zingiber officinale (GI)
Number of subjects: 17
Study 34933309 — intervention group
Group type: COMPARATOR
Intervention: Warm water only (WA)
Number of subjects: 17
Study 34933309 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water with GI
Number of subjects: 17
Study 34933309 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm water with MU
Number of subjects: 17
Study 34933309 — intervention group
Group type: EXPERIMENTAL
Intervention: General well-being and sleep quality assessments
Number of subjects: 17
Study 32072772 — intervention group
Group type: EXPERIMENTAL
Intervention: Exam room educational poster (English and Spanish)
Number of subjects: 965
Study 35938500 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused social marketing campaign promoting healthy children's meals
Number of subjects: 1686
Study 35938500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1686
Study 34414672 — intervention group
Group type: COMPARATOR
Intervention: Enpatoran 1, 3, 9, 25, 50, 100, or 200 mg single dose
Number of subjects: 96
Study 34414672 — intervention group
Group type: COMPARATOR
Intervention: Enpatoran 9, 25, or 200 mg once daily for 14 days
Number of subjects: 96
Study 34414672 — intervention group
Group type: COMPARATOR
Intervention: Enpatoran 25 or 50 mg twice daily for 14 days
Number of subjects: 96
Study 34414672 — intervention group
Group type: EXPERIMENTAL
Intervention: Enpatoran 25 mg single dose with food
Number of subjects: 96
Study 34414672 — intervention group
Group type: EXPERIMENTAL
Intervention: Enpatoran 200 mg single dose
Number of subjects: 96
Study 32942788 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetate (TA) 40 mg
Number of subjects: 30
Study 32942788 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetate (TA) 20 mg
Number of subjects: 30
Study 35027938 — intervention group
Group type: EXPERIMENTAL
Intervention: Inner Engineering Online (IEO) program
Number of subjects: 71
Study 35027938 — intervention group
Group type: COMPARATOR
Intervention: Control group (active control)
Number of subjects: 71
Study 32329766 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal naloxone
Number of subjects: 0
Study 32329766 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular naloxone
Number of subjects: 0
Study 34321056 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuina with herbal ointment
Number of subjects: 84
Study 34321056 — intervention group
Group type: COMPARATOR
Intervention: Herbal ointment (control group)
Number of subjects: 84
Study 33038022 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Hope Intervention (4-week program with four sessions: two face-to-face and two telephone follow-ups)
Number of subjects: 0
Study 33038022 — intervention group
Group type: COMPARATOR
Intervention: Control arm (renal education and social chats)
Number of subjects: 0
Study 34979880 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-threshold vibration
Number of subjects: 19
Study 34979880 — intervention group
Group type: EXPERIMENTAL
Intervention: Supra-threshold vibration
Number of subjects: 19
Study 34979880 — intervention group
Group type: COMPARATOR
Intervention: No vibration (control)
Number of subjects: 19
Study 33730928 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 μg/kg
Number of subjects: 136
Study 33730928 — intervention group
Group type: COMPARATOR
Intervention: 0.3 μg/kg
Number of subjects: 136
Study 33730928 — intervention group
Group type: COMPARATOR
Intervention: 0.5 μg/kg
Number of subjects: 136
Study 33730928 — intervention group
Group type: COMPARATOR
Intervention: 1.0 μg/kg
Number of subjects: 136
Study 35742483 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized VREs
Number of subjects: 20
Study 35742483 — intervention group
Group type: COMPARATOR
Intervention: Standard VREs
Number of subjects: 20
Study 32503545 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week medical respite care stay at a Red Cross facility
Number of subjects: 96
Study 32503545 — intervention group
Group type: COMPARATOR
Intervention: usual care (discharged without extra help)
Number of subjects: 96
Study 35380356 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 g/day of MCT oil
Number of subjects: 63
Study 35380356 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo formula (control)
Number of subjects: 63
Study 34080044 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone treatment
Number of subjects: 197
Study 34080044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 197
Study 34599865 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate (SC)
Number of subjects: 50
Study 34599865 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate (CA)
Number of subjects: 50
Study 35032434 — intervention group
Group type: EXPERIMENTAL
Intervention: Melflufen plus dexamethasone
Number of subjects: 495
Study 35032434 — intervention group
Group type: COMPARATOR
Intervention: Pomalidomide plus dexamethasone
Number of subjects: 495
Study 33357055 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention: Not specified in the abstract.
Number of subjects: 0
Study 33357055 — intervention group
Group type: COMPARATOR
Intervention: Control: Not specified in the abstract.
Number of subjects: 0
Study 34388037 — intervention group
Group type: EXPERIMENTAL
Intervention: Meaning-Centered Pain Coping Skills Training (MCPC) delivered across four 45- to 60-minute videoconference sessions.
Number of subjects: 30
Study 33686119 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Success Group (PDA closure achieved)
Number of subjects: 73
Study 33686119 — intervention group
Group type: COMPARATOR
Intervention: Intervention Failure Group (PDA closure not achieved)
Number of subjects: 73
Study 33686119 — intervention group
Group type: COMPARATOR
Intervention: Placebo Group
Number of subjects: 73
Study 33686119 — intervention group
Group type: COMPARATOR
Intervention: Low Risk Group
Number of subjects: 73
Study 34445834 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (400 mg/d)
Number of subjects: 64
Study 34445834 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group, average calcium intake 400 mg/d)
Number of subjects: 64
Study 32070034 — intervention group
Group type: EXPERIMENTAL
Intervention: Height‐adjustable workstation with supporting behaviour change strategies
Number of subjects: 146
Study 32070034 — intervention group
Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 146
Study 35460145 — intervention group
Group type: EXPERIMENTAL
Intervention: Jujube syrup, consumed twice a day for 8 weeks
Number of subjects: 46
Study 35460145 — intervention group
Group type: COMPARATOR
Intervention: Placebo, consumed twice a day for 8 weeks
Number of subjects: 46
Study 34126605 — intervention group
Group type: EXPERIMENTAL
Intervention: DIBH
Number of subjects: 80
Study 34126605 — intervention group
Group type: COMPARATOR
Intervention: FB
Number of subjects: 80
Study 34332638 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 30
Study 34332638 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 32402060 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25-29.9)
Number of subjects: 12521
Study 32402060 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity Grade 1 (BMI 30-34.9)
Number of subjects: 12521
Study 32402060 — intervention group
Group type: EXPERIMENTAL
Intervention: Low body weight (BMI < 22)
Number of subjects: 12521
Study 32402060 — intervention group
Group type: EXPERIMENTAL
Intervention: Continued 2-year weight loss
Number of subjects: 12521
Study 32402060 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain
Number of subjects: 12521
Study 34521417 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Number of subjects: 233
Study 34521417 — intervention group
Group type: COMPARATOR
Intervention: Glimepiride
Number of subjects: 233
Study 36007709 — intervention group
Group type: EXPERIMENTAL
Intervention: SAATH intervention (group exercise classes, mother-daughter discussions, peer group discussions)
Number of subjects: 160
Study 36007709 — intervention group
Group type: COMPARATOR
Intervention: Control group (PA education materials)
Number of subjects: 160
Study 33183463 — intervention group
Group type: EXPERIMENTAL
Intervention: Nanoparticle-loaded edaravone treatment (NET)
Number of subjects: 120
Study 33183463 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (CT)
Number of subjects: 120
Study 33183463 — intervention group
Group type: COMPARATOR
Intervention: Edaravone treatment (ET)
Number of subjects: 120
Study 35367918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 119
Study 35367918 — intervention group
Group type: COMPARATOR
Intervention: Health education (HealthEd)
Number of subjects: 119
Study 33094682 — intervention group
Group type: EXPERIMENTAL
Intervention: meloxicam IV 30 mg
Number of subjects: 55
Study 33094682 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 55
Study 32513473 — intervention group
Group type: EXPERIMENTAL
Intervention: CES-D scale scoring with a cut-off score of 30
Number of subjects: 348
Study 32726514 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous sarilumab (150 or 200 mg)
Number of subjects: 101
Study 32726514 — intervention group
Group type: COMPARATOR
Intervention: Intravenous tocilizumab (4 or 8 mg/kg)
Number of subjects: 101
Study 32726514 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs (sarilumab and tocilizumab)
Number of subjects: 101
Study 32767208 — intervention group
Group type: EXPERIMENTAL
Intervention: Gaming group (first-person shooter game)
Number of subjects: 35
Study 32767208 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 34158245 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib 25 mg PO daily with paclitaxel 80 mg/m2 IV weekly ×12 followed by doxorubicin 24 mg/m2 IV weekly + cyclophosphamide 60 mg/m2 PO daily with G-CSF support
Number of subjects: 70
Study 32971253 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 40226
Study 32971253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40226
Study 36355739 — intervention group
Group type: EXPERIMENTAL
Intervention: Pattern recognition control
Number of subjects: 2
Study 36355739 — intervention group
Group type: COMPARATOR
Intervention: Direct control
Number of subjects: 2
Study 36355739 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG signal analysis
Number of subjects: 2
Study 34096845 — intervention group
Group type: EXPERIMENTAL
Intervention: Health care-specific websites (eg, Healthgrades, Zocdoc, Vitals, WebMD)
Number of subjects: 0
Study 34096845 — intervention group
Group type: COMPARATOR
Intervention: General consumer sites (eg, Google, Yelp)
Number of subjects: 0
Study 32204706 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with ASD (case group)
Number of subjects: 30
Study 34452959 — intervention group
Group type: EXPERIMENTAL
Intervention: High fibre supplement (resistant starch)
Number of subjects: 60
Study 34452959 — intervention group
Group type: COMPARATOR
Intervention: Placebo (digestible starch)
Number of subjects: 60
Study 34817559 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA screening (three invitations at 4-year intervals from 1996 to 2007)
Number of subjects: 78606
Study 34817559 — intervention group
Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 78606
Study 33619944 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based cardiac telerehabilitation (HBCT)
Number of subjects: 44
Study 33619944 — intervention group
Group type: COMPARATOR
Intervention: Center-based cardiac rehabilitation (CBCR)
Number of subjects: 44
Study 33619944 — intervention group
Group type: COMPARATOR
Intervention: Both groups (HBCT and CBCR)
Number of subjects: 44
Study 32796391 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-inflammatory combination therapy
Number of subjects: 39
Study 32796391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 34644372 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 296
Study 34644372 — intervention group
Group type: COMPARATOR
Intervention: Brentuximab vedotin (BV)
Number of subjects: 296
Study 34706841 — intervention group
Group type: EXPERIMENTAL
Intervention: MINHAI PCV13
Number of subjects: 900
Study 34706841 — intervention group
Group type: COMPARATOR
Intervention: Hib
Number of subjects: 900
Study 32216832 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) combined with bright light therapy (BLT) - one face-to-face session on sleep strategies, one telephone call, seven email packages, and wearing Luminette® light glasses for 20 minutes each morning for 6 weeks.
Number of subjects: 0
Study 32216832 — intervention group
Group type: COMPARATOR
Intervention: Relaxation audio-enhanced treatment as usual (TAU+) - two relaxation audio tracks via email.
Number of subjects: 0
Study 32203960 — intervention group
Group type: EXPERIMENTAL
Intervention: Static half squat plus WBV (HSV)
Number of subjects: 12
Study 32203960 — intervention group
Group type: EXPERIMENTAL
Intervention: Static half squat without WBV (HSWV)
Number of subjects: 12
Study 32203960 — intervention group
Group type: COMPARATOR
Intervention: Rest (REST)
Number of subjects: 12
Study 34606090 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 0
Study 34606090 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygenation targets
Number of subjects: 0
Study 34606090 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 34606090 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluids
Number of subjects: 0
Study 32845062 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic surgery
Number of subjects: 363
Study 32845062 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 363
Study 32845062 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 363
Study 34297441 — intervention group
Group type: EXPERIMENTAL
Intervention: Shape Up-LD
Number of subjects: 50
Study 34297441 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 50
Study 34916532 — intervention group
Group type: EXPERIMENTAL
Intervention: star‐VIBE sequence (Group A)
Number of subjects: 60
Study 34916532 — intervention group
Group type: COMPARATOR
Intervention: 3D‐VIBE sequence (Group B)
Number of subjects: 60
Study 36060925 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocin (30 mg tablets, three consecutive doses, 1 day before to 1 day after CM exposure)
Number of subjects: 110
Study 36060925 — intervention group
Group type: COMPARATOR
Intervention: Control (standard hydration therapy only)
Number of subjects: 110
Study 32571229 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of Motor and Process Skills motor scale
Number of subjects: 144
Study 32571229 — intervention group
Group type: EXPERIMENTAL
Intervention: 30s-Chair Stand Test
Number of subjects: 144
Study 32571229 — intervention group
Group type: COMPARATOR
Intervention: Other measures
Number of subjects: 144
Study 36435539 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaginal retraining (IR)
Number of subjects: 384
Study 34467824 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Care Transitions Intervention (ECTI) with peer support
Number of subjects: 0
Study 34467824 — intervention group
Group type: COMPARATOR
Intervention: Care Transitions Intervention (CTI)
Number of subjects: 0
Study 36214036 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care received during COVID-19 lockdown
Number of subjects: 49
Study 36214036 — intervention group
Group type: EXPERIMENTAL
Intervention: Home delivery of chronic medication
Number of subjects: 49
Study 36214036 — intervention group
Group type: EXPERIMENTAL
Intervention: Referrals to community health workers and telephonic patient follow-up
Number of subjects: 49
Study 33788457 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrothermal acupuncture therapy applied at Guanyuan (CV 4), Qihai (CV 6), Zusanli (ST 36), Hegu (LI 4), Sanyinjiao (SP 6), 30 min each treatment, once a day for 5 days
Number of subjects: 60
Study 33788457 — intervention group
Group type: COMPARATOR
Intervention: Opioid painkillers (oxycodone hydrochloride prolonged-release tablet or morphine sulfate sustained-release tablet)
Number of subjects: 60
Study 35311718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT) 5 times a week for 30 minutes each time over a period of 3 weeks
Number of subjects: 32
Study 35311718 — intervention group
Group type: COMPARATOR
Intervention: Control group (CT) receiving medication and routine rehabilitation training
Number of subjects: 32
Study 32949864 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted treatment (TT) with fenbendazole at 22, 27 and 36 weeks post‐placement (WPP)
Number of subjects: 6
Study 32949864 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (CT) at 27 WPP
Number of subjects: 6
Study 32949864 — intervention group
Group type: COMPARATOR
Intervention: Untreated (UT) control groups
Number of subjects: 6
Study 33057739 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS) for 30 min once a week for 12 weeks.
Number of subjects: 106